{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-002704","form_type":"8-K","ticker":"SPRB","cik":"0001683553","company_name":"SPRUCE BIOSCIENCES, INC.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.106439+00:00","generated_at":"2026-06-07T02:22:48.257218+00:00","sec_items":["2.02","9.01","7.01","8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Spruce Biosciences provides cash update; adult CAH trials enrollment complete; topline data expected March 2024","bullets":["Cash and equivalents ~$96M as of Dec 31, 2023; 41.0M shares outstanding.","CAHmelia-203 (N=96) and CAHptain-205 (N=30) enrollment complete, surpassing targets.","CAHmelia-204 enrollment to finish Jan 2024 (N~98); topline results from CAHmelia-203 and CAHptain-205 expected March 2024.","Baseline characteristics: CAHmelia-203 mean A4 1,149 ng/dL on 27 mg/day GC; CAHmelia-204 mean A4 214 ng/dL on 35 mg/day GC.","Cash runway into first half of 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-002704","json":"https://secwatch.observer/filing/0000950170-24-002704.json","markdown":"https://secwatch.observer/filing/0000950170-24-002704.md","text":"https://secwatch.observer/filing/0000950170-24-002704.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1683553/000095017024002704/0000950170-24-002704-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1683553/000095017024002704/sprb-20240104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:22:48.257218+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}